Table 1.
The baseline clinical data of the immunohistochemical score of IGFBP7.
| Group | IGFBP7 IHC Score | p Value | |
|---|---|---|---|
| Low (0–6) | High (7–12) | ||
| Numbers, n (%) | 44 (55%) | 36 (45%) | |
| Gender | 0.003 ** | ||
| male | 40 (50%) | 23 (28.7%) | |
| female | 4 (5%) | 13 (16.2%) | |
| Age, mean ± sd | 64.636 ± 10.625 | 61.389 ± 12.133 | 0.206 |
| Depth of invasion | 0.026 * | ||
| T1 and T2 | 8 (10%) | 0 (0%) | |
| T3 | 14 (17.5%) | 13 (16.2%) | |
| T4 | 22 (27.5%) | 23 (28.7%) | |
| Lymph node | 0.030 * | ||
| N0 | 13 (16.2%) | 4 (5%) | |
| N1 | 8 (10%) | 6 (7.5%) | |
| N2 | 14 (17.5%) | 8 (10%) | |
| N3 | 9 (11.2%) | 18 (22.5%) | |
| Metastasis | 0.008 ** | ||
| M0 | 44 (55%) | 29 (36.2%) | |
| M1 | 0 (0%) | 7 (8.8%) | |
| Clinical stage | 0.390 | ||
| II | 15 (18.8%) | 11 (13.8%) | |
| II–III | 11 (13.8%) | 14 (17.5%) | |
| III | 18 (22.5%) | 11 (13.8%) | |
| Lymphovascular invasion | 0.027 * | ||
| yes | 20 (31.7%) | 9 (14.3%) | |
| no | 14 (22.2%) | 20 (31.7%) | |
| Nerve invasion | 0.687 | ||
| yes | 14 (23.7%) | 9 (15.3%) | |
| No | 20 (33.9%) | 16 (27.1%) | |
(* p < 0.05, ** p < 0.01).